Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Extended-infusion Beta-Lactams in Septic Shock
NCT02820987Phase 3Completed
- Sponsor
- CHU de Besançon
- Start
- Sep 2016
- Primary completion
- Oct 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of meropenem, piperacillin + tazobactam, cefepime in septic shock, sponsored by CHU de Besançon. Started Sep 2016; status: completed.
02
Drugs
meropenempiperacillin + tazobactamcefepime
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02820987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820987.